Proactive Investors - Run By Investors For Investors

ANGLE raises £18mln as it gears up for Parsortix commercialisation

If all goes to plan, ANGLE’s Parsortix cancer-detecting blood test could get the green light from US regulators in early 2020, and bosses are strengthening the balance sheet ahead of that
parsortix
Parsortix analyses blood for signs of cancer

ANGLE PLC (LON:AGL) shares pushed higher on Tuesday in spite of news the firm is raising £18mln from new and existing investors as it gears up for potential commercialisation of its Parsortix liquid biopsy early next year.

Parsortix is a simple blood test which can help doctors spot signs of cancer at an early stage.

READ: ANGLE scores early success in ovarian cancer trial

Results from a recent clinical trial showed the system was able to capture and harvest cancer cells from the blood of a significant proportion of metastatic breast cancer patients.

The plan now is to make a US Food and Drug Administration regulatory submission in the final quarter of 2019. If all goes well, ANGLE could receive approval in early 2020.

Although the company has been able to make some sales already – 200 or so devices are used by research organisations – regulatory approval would open up a huge new market.

No discount needed

Of the £18mln, which is being raised by the issue of 29.3mln new shares at 61.5p apiece, £11mln will be used to strengthen the balance sheet in preparation for negotiation of potential corporate partnership deals.

That chunk of money will also extend the firm’s cash runway “significantly beyond” the expected timeframe for potential FDA clearance and completion of the ongoing ovarian cancer study.

Away from that, ANGLE will spend £2mln further refining the Parsortix system, another £2mln on establishing a breast cancer remission monitoring study, and the same amount again on setting up a service laboratory to support pharma services and accelerate clinical adoption.

That leaves £1mln left over, which will be used to develop techniques for culturing circulating tumour cells (CTCs) for drug testing.

Balance sheet strengthened

“We are grateful for the strong support of existing and new shareholders as we build our business to address the global liquid biopsy market,” said chief executive and founder Andrew Newland.

“As well as strengthening the company's balance sheet in preparation for negotiating corporate partnerships, the proceeds from the placing will allow us to establish a clinically approved service laboratory to drive business from pharmaceutical drug trials and accelerate use of the Parsortix system for treating patients.”

In afternoon trading, ANGLE shares were 4.9% higher at 64.50p.

 -- Updates share price --

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use